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SCIENTIFIC OPINION 
Scientific Opinion Part I on the substantiation of health claims related to 
various food(s)/food constituent(s) not supported by pertinent human data 
(ID 411, 559, 1174, 1184, 1197, 1380, 1409, 1656, 1667, 1670, 1763, 1767, 
1806, 1884, 1908, 1997, 2141, 2159, 2243, 2244, 2325, 2331, 2333, 2336, 
2652, 2717, 2727, 2752, 2788, 2861, 2870, 2885, 2894, 3077, 3101, 3516, 
3595, 3726, 4252, 4288, 4290, 4406, 4509, 4709) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to various food(s)/food constituent(s) not supported by pertinent human data. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The references provided in relation to the claims evaluated in this opinion included studies which 
assessed the effects of food(s)/food constituent(s) other than the food(s)/food constituent(s) which are 
the subject of the claims, and/or investigated health outcomes unrelated to the claimed effects. No 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1198, EFSA-Q-2008-1346, EFSA-Q-2008-1913, 
EFSA-Q-2008-1923, EFSA-Q-2008-1936, EFSA-Q-2008-2117, EFSA-Q-2008-2146, EFSA-Q-2008-2392, EFSA-Q-
2008-2403, EFSA-Q-2008-2406, EFSA-Q-2008-2496, EFSA-Q-2008-2500, EFSA-Q-2008-2539, EFSA-Q-2008-2617, 
EFSA-Q-2008-2641, EFSA-Q-2008-2730, EFSA-Q-2008-2874, EFSA-Q-2008-2892, EFSA-Q-2008-2976, EFSA-Q-
2008-2977, EFSA-Q-2008-3058, EFSA-Q-2008-3064, EFSA-Q-2008-3066, EFSA-Q-2008-3069, EFSA-Q-2008-3385, 
EFSA-Q-2008-3450, EFSA-Q-2008-3460, EFSA-Q-2008-3485, EFSA-Q-2008-3521, EFSA-Q-2008-3594, EFSA-Q-
2008-3603, EFSA-Q-2008-3618, EFSA-Q-2008-3627, EFSA-Q-2008-3809, EFSA-Q-2008-3833, EFSA-Q-2008-4243, 
EFSA-Q-2008-4320, EFSA-Q-2008-4448, EFSA-Q-2008-4962, EFSA-Q-2010-00241, EFSA-Q-2010-00243, EFSA-Q-
2010-00359, EFSA-Q-2010-00462, EFSA-Q-2010-00662, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this Scientific Opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.  
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human studies, which investigated the effects of the food(s)/food constituent(s) on appropriate 
measures of the claimed effects, were provided. The Panel considers that no conclusions can be drawn 
from any of the references provided for the scientific substantiation of the claims evaluated in this 
opinion. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food(s)/food constituent(s) and the claimed effects 
evaluated in this opinion. 
KEY WORDS 
Appetite, satiety, body weight, LDL cholesterol, blood pressure, cardiac function, oxidative damage, bowel 
function, UV-induced photo-oxidative damage, post-prandial glycaemic responses, venous walls, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
6
.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:  
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (“beneficial to human health”);  
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Relevance of the claimed effect to human health 
1.1. Increase in appetite after unintentional weight loss leading to an increase in energy 
intake (ID 411, 2141) 
The claimed effects are “appetite (stimulation)” and “appetite/digestion”. The Panel assumes that the 
target population is underweight individuals who wish to increase their energy intake. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
increase in appetite after unintentional weight loss. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6 See footnote 5 
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The Panel considers that an increase in appetite after unintentional weight loss leading to an increase 
in energy intake, if sustained, might be a beneficial physiological effect.  
1.2. Increase in satiety leading to a reduction in energy intake (ID 1656, 1884, 2870, 2894, 
4252) 
The claimed effects are “satiety/weight management/promotion of CCK release and soy foods”, 
“alginate forms a gel in the stomach and promotes an immediate feeling of satiety. It may also trap a 
portion of HCA. Piperine increases the bioavailability of the un-trapped HCA and enhances satiety”, 
“satiety”, and “weight management/satiety”. The Panel assumes that the target population is the 
general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in satiety. Satiety is the decrease in the motivation to eat after consumption of food. The 
effect may persist up to several hours, may reduce energy intake either at the next meal or across the 
day and, if sustained, may lead to a reduction in body weight. 
The Panel considers that an increase in satiety leading to a reduction in energy intake, if sustained, 
might be a beneficial physiological effect. 
1.3. Contribution to the maintenance or achievement of a normal body weight (ID 559, 
1380, 1656, 1806, 2243, 2325, 2331, 2333, 2336, 2717, 2727, 2788, 2870, 3726, 4252, 
4709) 
The claimed effects are “weight control; carbohydrate metabolism and insulin sensitivity”, “weight 
management”, “satiety/weight management/promotion of CCK release and soy foods”, “weight 
control”, “weight loss management, carbohydrate & lipid metabolism improvement”, “weight loss 
management, acid base balancer”, “weight management, thermogenesis”, “amincissement”, 
“slimming (cellulitis draining)”, and “weight management/satiety”. The Panel assumes that the target 
population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the 
maintenance or achievement of a normal body weight. 
Weight management and weight control can be interpreted as contribution to the maintenance of a 
normal body weight. In this context, weight loss in overweight individuals without achieving a normal 
body weight is considered to be a beneficial physiological effect. 
The Panel considers that contribution to the maintenance or achievement of a normal body weight is a 
beneficial physiological effect. 
1.4. Maintenance of normal blood LDL-cholesterol concentrations (ID 1763, 2861, 3101, 
4406) 
The claimed effects are “cardiovascular health”, “control of blood lipids”, and “blood cholesterol”. 
The Panel assumes that the target population is the general population.  
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the maintenance of normal blood LDL-cholesterol 
concentrations. 
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial 
physiological effect. 
Health claims related to various food(s)/food constituent(s) 
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1.5. Maintenance of normal blood pressure (ID 2159) 
The claimed effect is “heart health”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
maintenance of normal blood pressure.  
Blood pressure is the pressure (force per unit area) exerted by circulating blood on the walls of blood 
vessels. Elevated blood pressure, by convention above 140 mmHg (systolic) and/or 90 mmHg 
(diastolic), may compromise the normal arterial and cardiac function. 
The Panel considers that maintenance of normal blood pressure is a beneficial physiological effect. 
1.6. Maintenance of normal cardiac function (ID 1767, 3595, 4509) 
The claimed effects are “cardiovascular health”, “excellent source of sulforaphane known to help in 
the management of heart health”, and “help restoration of myocardial tissue”. The Panel assumes that 
the target population is the general population. 
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects relate to the maintenance of normal cardiac function. 
The Panel considers that maintenance of normal cardiac function is a beneficial physiological effect. 
1.7. Protection of DNA, proteins and lipids from oxidative damage (ID 1174, 1184, 1197, 
1667, 1997, 2244, 2652, 3077) 
The claimed effects are “heart health vascular health”, “cardiovascular system”, “maintenance of 
cardiovascular system”, “for cardiovascular health”, “antioxidant properties/source of anthocyanins 
and polyphenols with antioxidant activity”, “antioxidant properties”, “antioxidant effects”, and 
“immune system, antioxidant properties”. The Panel assumes that the target population is the general 
population.  
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to the protection of cells and molecules from oxidative damage 
caused by free radicals. 
Reactive oxygen species (ROS) including several kinds of radicals are generated in biochemical 
processes (e.g. respiratory chain) and as a consequence of exposure to exogenous factors 
(e.g. radiation, pollutants). These reactive intermediates damage biologically relevant molecules such 
as DNA, proteins and lipids if they are not intercepted by the antioxidant network which includes free 
radical scavengers such as antioxidant nutrients.  
The Panel considers that protection of DNA, proteins and lipids from oxidative damage may be a 
beneficial physiological effect. 
1.8. Changes in bowel function (ID 1409, 2141, 2752, 2885, 3516) 
The claimed effects are “D/L-lactic acid - L(+)lactic acid activate the gut motility”, 
“appetite/digestion”, “improve digestion/transit”, “digestion/intestinal tract”, and “digestion". The 
Panel assumes that the target population is the general population.  
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effects refer to changes in bowel function. 
Health claims related to various food(s)/food constituent(s) 
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The Panel considers that changes in bowel function such as reduced transit time, more frequent bowel 
movements, increased faecal bulk, or softer stools may be a beneficial physiological effect, provided 
that these changes do not result in diarrhoea. 
1.9. Protection of lipids in the skin from UV-induced photo-oxidative damage (ID 4288, 
4290) 
The claimed effect is “antioxidant action”. The Panel assumes that the target population is the general 
population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
protection of lipids in the skin from UV-induced photo-oxidative damage. 
The Panel considers that the protection of lipids in the skin from UV-induced photo-oxidative damage 
is a beneficial physiological effect. 
1.10. Reduction of post-prandial glycaemic responses (ID 559) 
The claimed effect is “weight control; carbohydrate metabolism and insulin sensitivity”. The Panel 
assumes that the target population is individuals who wish to reduce their post-prandial glycaemic 
responses. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the 
reduction of post-prandial glycaemic responses.  
Postprandial glycaemia is interpreted as the elevation of blood glucose concentrations after 
consumption of a food and/or meal. This function is a normal physiological response which varies in 
magnitude and duration and which may be influenced by the chemical and physical nature of the food 
or meal consumed, as well as by individual factors (Venn and Green, 2007). Reducing post-prandial 
glycaemic responses may be beneficial to subjects with, for example, impaired glucose tolerance as 
long as post-prandial insulinaemic responses are not disproportionally increased. Impaired glucose 
tolerance is common in the general population of adults. 
The Panel considers that reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) may be a beneficial physiological effect. 
1.11. Maintenance of elasticity and strength of the venous walls (ID 1670, 1908) 
The claimed effect is “vascular health”. The Panel assumes that the target population is the general 
population.  
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to the maintenance of elasticity and strength of the venous 
walls.  
The Panel considers that maintenance of elasticity and strength of the venous walls is a beneficial 
physiological effect.  
Health claims related to various food(s)/food constituent(s) 
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2. Scientific substantiation of the claimed effect 
2.1. Increase in appetite after unintentional weight loss leading to an increase in energy 
intake (ID 411, 2141) 
The references provided in relation to these claims included textbooks which did not provide any 
original data for the scientific substantiation of the claims. The Panel considers that no conclusions 
can be drawn from these references for the scientific substantiation of the claims. 
No human studies which investigated the effect of the food(s)/food constituent(s) on appetite ratings, 
energy intake or body weight were provided in relation to any of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and a sustained increase in appetite after unintentional weight loss leading to an increase in 
energy intake.  
2.2. Increase in satiety leading to a reduction in energy intake (ID 1656, 1884, 2870, 2894, 
4252) 
The references provided in relation to these claims included narrative reviews on the regulation of 
appetite, energy intake and body weight which did not provide any original data for the scientific 
substantiation of the claims, addressed the effects of food(s)/food constituent(s) other than those 
which are the subject of the claims, and/or investigated health outcomes (e.g. post-prandial blood 
glucose and insulin responses, body composition) unrelated to the claimed effect. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claims. 
Some human intervention studies, which investigated the effect of the food(s)/food constituent(s) on 
appetite ratings and/or subsequent food intake and/or secretion of hormones with a putative role on 
the regulation of food intake (e.g. glucagon-like peptide-1, cholecystokinin, ghrelin) following a 
single meal or over 24 hours, were provided. The Panel notes that none of these studies tested the 
sustainability of an effect of the food(s)/food constituent(s) on appetite ratings and subsequent energy 
intake (i.e. effects were tested on a single occasion and no information was provided on the repeated 
consumption of the food(s)/food constituent(s)). The Panel considers that no conclusions can be 
drawn from these studies for the scientific substantiation of a claim on a sustained increase in satiety 
leading to a reduction in energy intake. 
No human studies which investigated the effects of the food(s)/food constituent(s) on a sustained 
increase in satiety leading to a reduction in energy intake were provided in relation to any of the 
claims evaluated in this section. 
A number of animal studies which addressed the effects of the food(s)/food constituent(s) on food 
intake, body weight, and/or secretion of hormones with a putative role on the regulation of food 
intake, and a number of animal and in vitro studies which addressed the mechanisms by which the 
food(s)/constituent(s) could exert the claimed effect were also provided. The Panel considers that, in 
the absence of human studies from which conclusions could be drawn for the scientific substantiation 
of the claim, the evidence provided in animal and in vitro studies is not sufficient to predict the 
occurrence of an effect of the consumption of the food(s)/food constituent(s) on an increase in satiety 
leading to a reduction in energy intake in humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and a sustained increase in satiety leading to a reduction in energy intake. 
Health claims related to various food(s)/food constituent(s) 
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2.3. Contribution to the maintenance or achievement of a normal body weight (ID 559, 
1380, 1656, 1806, 2243, 2325, 2331, 2333, 2336, 2717, 2727, 2788, 2870, 3726, 4252, 
4709) 
Most of the references provided in relation to these claims were narrative reviews on the potential 
health effects of different food(s)/food constituent(s) which did not provide any original data for the 
scientific substantiation of the claims, addressed the effects of food(s)/food constituent(s) other than 
those which are the subject of the claims, and/or investigated health outcomes (e.g. delayed gastric 
emptying, appetite ratings and/or subsequent food intake following a single meal or over 24 hours, 
energy expenditure, post-prandial blood glucose responses, insulin sensitivity and/or long-term blood 
glucose control, treatment of chronic venous insufficiency, bioavailability of different food 
constituents, on plasma concentrations of carotenoids, blood lipids and/or lipid metabolism, 
antioxidant properties and/or oxidative stress) other than body weight. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claims. 
For ID 2243 and 2325, summaries of two human intervention studies on the effects of the food 
constituents on body weight were provided. However, the limited methodological data available in the 
summaries did not allow a complete scientific evaluation. The Panel considers that no conclusions can 
be drawn from these references for the scientific substantiation of the claims. 
For ID 1656 and 2870, some internal reports identified as proprietary by the company reported on 
human intervention studies on the effects of the food constituents on body weight. The Panel notes 
that Regulation (EC) No 1924/2006 does not foresee the protection of proprietary data for health 
claims under Article 13.1 of the Regulation and therefore considers that these data cannot be used for 
the scientific substantiation of the claims. 
No relevant human studies which investigated the effects of the food(s)/food constituent(s) on 
changes in body weight were provided in relation to any of the claims evaluated in this section.  
A number of animal studies which addressed the effects of some of the food(s)/constituent(s) on body 
weight, and a number of animal and in vitro studies which addressed the mechanisms by which the 
food(s)/constituent(s) could exert the claimed effect were also provided. The Panel considers that 
evidence provided in animal and in vitro studies is not sufficient to predict the occurrence of an effect 
of the consumption of the food(s)/food constituent(s) on body weight in vivo in humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and contribution to the maintenance or achievement of a normal body weight. 
2.4. Maintenance of normal blood LDL-cholesterol concentrations (ID 1763, 2861, 3101, 
4406)  
The references provided in relation to these claims were book chapters and narrative reviews on the 
potential health effects of different food(s)/food constituent(s) which did not provide any original data 
for the scientific substantiation of the claims, addressed the effects of food(s)/food constituent(s) 
other than those which are the subject of the claims, and/or investigated health outcomes (e.g. 
resistance of LDL particles to peroxidation, liver steatosis, platelet aggregation, incidence of chronic 
diseases such as ischaemic heart disease, cancer, or asthma) other than blood cholesterol 
concentrations. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on blood 
LDL-cholesterol concentrations were provided in relation to any of the claims evaluated in this 
section. 
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A number of animal studies which addressed the effects of some of the food(s)/food constituent(s) on 
the blood lipid profile, and a number of animal and in vitro studies which addressed the mechanisms 
by which the food(s)/food constituent(s) could exert the claimed effect were provided (e.g. activity of 
3-hydroxy-3-methyl-glutaryl-CoA reductase, acyl CoA:cholesterol tranferases and/or microsomal 
triglyceride transfer protein in the liver). The Panel considers that evidence provided in animal and 
in vitro studies is not sufficient to predict the occurrence of an effect of the consumption of the 
food(s)/food constituent(s) on blood LDL-cholesterol concentrations in vivo in humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and maintenance of normal blood LDL-cholesterol concentrations. 
2.5. Maintenance of normal blood pressure (ID 2159) 
One reference on the antioxidant properties of different plant extracts and two reviews which did not 
address the effects of the food, which is the subject of the claim, on blood pressure were cited in 
relation to this claim. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
No human studies, which investigated the effects of the food on blood pressure were provided in 
relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food which is the subject of the claim evaluated in this section and maintenance of 
normal blood pressure. 
2.6. Maintenance of normal cardiac function (ID 1767, 3595, 4509) 
The references provided in relation to these claims were book chapters and narrative reviews on the 
potential health effects of different food(s)/food constituent(s) which did not provide any original data 
for the scientific substantiation of the claims, addressed the effects of food(s)/food constituent(s) 
other than those which are the subject of the claims, and/or investigated health outcomes (e.g. 
treatment of infections, resistance of LDL particles to peroxidation, liver steatosis, platelet 
aggregation, incidence of chronic diseases such as ischaemic heart disease, cancer, asthma) unrelated 
to the claimed effect. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on heart function 
were provided in relation to any of the claims evaluated in this section. 
One animal study on a mice model of atherosclerosis was provided. The Panel considers that evidence 
provided in animal studies is not sufficient to predict the occurrence of an effect of the consumption 
of the food(s)/food constituent(s) on maintenance of normal cardiac function in humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and maintenance of normal cardiac function. 
2.7. Protection of DNA, proteins and lipids from oxidative damage (ID 1174, 1184, 1197, 
1667, 1997, 2244, 2652, 3077) 
Most of the references provided in relation to these claims addressed potential health effects of 
dietary antioxidants in general, of food(s)/food constituent(s) other than those which are the subject of 
Health claims related to various food(s)/food constituent(s) 
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the claims, and/or reported on claimed effects other than the protection of body cells and molecules 
from oxidative damage. The latter included references on the development or progression of acute or 
chronic diseases (e.g. immune dysfunction/susceptibility to infections, cardiovascular diseases, 
cancer, and degenerative diseases, among others) presumed to be associated with increased levels of 
oxidative stress and where oxidative damage to cells or molecules has not been considered as an 
outcome. The Panel considers that no conclusions can be drawn from these references for the 
scientific substantiation of the claim. 
Some intervention studies in humans which investigated the effects of the food(s)/food constituent(s) 
on the overall antioxidant capacity of plasma assessed by different methods have been provided. 
These methods included total reactive antioxidant potential (TRAP), trolox-equivalent antioxidant 
capacity (TEAC), ferric reducing ability of plasma (FRAP), oxygen radical absorbance capacity 
(ORAC), and dichlorofluorescein (DCF) fluorescence. The Panel considers that the evidence provided 
in these studies does not predict the occurrence of an effect of the food(s)/food constituent(s) on the 
protection of body cells and molecules from oxidative damage (Dalle-Donne et al., 2006; Griffiths et 
al., 2002; Knasmuller et al., 2008; Mayne, 2003).  
A number of intervention studies assessed changes in antioxidant enzymes (e.g. superoxide dismutase 
(SOD), catalase (CAT), glutathione peroxidase (GPx), haemoxigenase) and compounds (e.g. 
glutathione (GSH)) belonging to the antioxidant network system, or on HDL-associated paraoxonases 
(e.g. PON-1). The Panel notes that induction of antioxidant enzymes and HDL-associated 
paraoxonases provides an indication of response to oxidative stress, but it is not specific (e.g. 
induction of antioxidant enzymes may also be achieved in response to the pro-oxidant effect of a 
dietary component) and does not reflect oxidative damage to cells or molecules (Niki, 2009). 
Some intervention studies in humans which investigated the effects of the food(s)/ food constituent(s) 
on markers of lipid peroxidation have been provided. Such markers are thiobarbituric acid-reactive 
substances (TBARS), malondialdehyde (MDA) and/or oxidation lag time of LDL ex vivo and/or 
autoantibodies against oxidised LDL particles. The Panel considers that both TBARS and MDA, 
when used alone, are not reliable markers of lipid peroxidation (Griffiths et al., 2002; Knasmuller et 
al., 2008; Lykkesfeldt, 2007). The Panel also considers that no evidence has been provided to 
establish that the oxidation lag time of LDL particles ex vivo or that autoantibodies against oxidised 
LDL particles predict the resistance of LDL particles to peroxidation in vivo (Griffiths et al., 2002; 
Lapointe et al., 2006; Verhoye and Langlois, 2009).  
No human studies which investigated the effects of the food(s)/food constituent(s) on reliable markers 
of oxidative damage to body cells or to molecules such as DNA, proteins and lipids were provided in 
relation to any of the claims evaluated in this section. 
A number of in vitro studies were provided which addressed the antioxidant properties of different 
food(s)/food constituent(s), either by testing their capacity to scavenge free radicals under controlled 
conditions or by testing their capacity to prevent or delay protein, lipid or DNA oxidation in different 
in vitro models. Also, studies were provided on the relationship between the intake of the food(s)/food 
constituent(s) and the claimed effect by measuring markers of protein, lipid and/or DNA oxidation in 
animals, either in vivo or ex vivo. The Panel considers that evidence provided in animal and in vitro 
studies is not sufficient to predict the occurrence of an effect of the food(s)/food constituent(s) 
consumption on the protection of body cells and molecules from oxidative damage in vivo in humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and protection of DNA, proteins or lipids from oxidative damage. 
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2.8. Changes in bowel function (ID 1409, 2141, 2752, 2885, 3516) 
The references provided in relation to these claims were textbooks, narrative reviews or monographs 
which did not provide any original data for the scientific substantiation of the claims, studies which 
addressed the effects of food(s)/food constituent(s) other than those which are the subject of the 
claims, and/or investigated health outcomes (e.g. glucose tolerance and lipid metabolism, hydrogen 
and methane production in the gastro-intestinal tract) unrelated to the claimed effect. The Panel 
considers that no conclusions can be drawn from these references for the scientific substantiation of 
the claim. 
No human studies which investigated the effects of the food(s)/food constituent(s) on measures of 
bowel function were provided in relation to any of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and changes in bowel function. 
2.9. Protection of lipids in the skin from UV-induced photo-oxidative damage (ID 4288, 
4290) 
The references provided in relation to these claims were monographs which addressed food(s)/food 
constituent(s) other than those which are the subject of the claims. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on protection of 
lipids in the skin from UV-induced photo-oxidative damage were provided in relation to any of the 
claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and protection of lipids in the skin from UV-induced photo-oxidative damage. 
2.10. Reduction of post-prandial glycaemic responses (ID 559) 
The references provided in relation to this claim included narrative reviews which did not provide any 
original data for the scientific substantiation of the claims and studies which assessed the effects of 
food(s)/food constituent(s) other than the food which is the subject of the claim. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claim. 
No human studies which investigated the effects of the food on reduction of post-prandial glycaemic 
responses were provided in relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food which is the subject of the claim evaluated in this section and reduction of 
post-prandial glycaemic responses. 
2.11. Maintenance of elasticity and strength of the venous walls (ID 1670, 1908) 
The references provided in relation to these claims included human intervention and animal studies on 
the effects of the food constituent(s), either alone or in combination with other substances, on health 
outcomes (e.g. pharmacokinetics, treatment of chronic venous insufficiency, treatment of retinal 
venous occlusion, red blood cell aggregability, lipid peroxidation, profibrinolytic activity) unrelated 
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to the claimed effect. The Panel considers that no conclusions can be drawn from these references for 
the scientific substantiation of the claim. 
No human studies which investigated the effects of the food constituent(s) on maintenance of the 
elasticity and strength of the venous walls were provided in relation to any of the claims evaluated in 
this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food constituent(s) which are the subject of the claims evaluated in this section 
and maintenance of the elasticity and strength of the venous walls. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 A cause and effect relationship has not been established between the consumption of the 
food(s)/food constituent(s) and the claimed effects evaluated in this opinion. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1198, 
EFSA-Q-2008-1346, EFSA-Q-2008-1913, EFSA-Q-2008-1923, EFSA-Q-2008-1936, EFSA-Q-2008-
2117, EFSA-Q-2008-2146, EFSA-Q-2008-2392, EFSA-Q-2008-2403, EFSA-Q-2008-2406, EFSA-Q-
2008-2496, EFSA-Q-2008-2500, EFSA-Q-2008-2539, EFSA-Q-2008-2617, EFSA-Q-2008-2641, 
EFSA-Q-2008-2730, EFSA-Q-2008-2874, EFSA-Q-2008-2892, EFSA-Q-2008-2976, EFSA-Q-2008-
2977, EFSA-Q-2008-3058, EFSA-Q-2008-3064, EFSA-Q-2008-3066, EFSA-Q-2008-3069, EFSA-Q-
2008-3385, EFSA-Q-2008-3450, EFSA-Q-2008-3460, EFSA-Q-2008-3485, EFSA-Q-2008-3521, 
EFSA-Q-2008-3594, EFSA-Q-2008-3603, EFSA-Q-2008-3618, EFSA-Q-2008-3627, EFSA-Q-2008-
3809, EFSA-Q-2008-3833, EFSA-Q-2008-4243, EFSA-Q-2008-4320, EFSA-Q-2008-4448, EFSA-Q-
2008-4962, EFSA-Q-2010-00241, EFSA-Q-2010-00243, EFSA-Q-2010-00359, EFSA-Q-2010-00462, 
EFSA-Q-2010-00662). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
7
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
8
  
Foods are commonly involved in many different functions
9
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
7 OJ L12, 18/01/2007 
8 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
9 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to various food(s)/food constituent(s) that are not supported 
by pertinent human data, including conditions of use from similar claims, as proposed in the 
Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
411 Mineralwasser/ 
Natriumchlorid. 
Clarification provided 
Mineral water/sodium 
chloride. 
Appetit 
(Anregung). 
Clarification provided 
Appetite (stimulation). 
[In German:] zur Anregung des 
Appetits. 
Clarification provided 
To stimulate the appetite. 
Conditions of use 
- ab 200 mg/l Natrium und 200 mg/l Chlorid (siehe EG-Mineralwasser-Richtlinie). 
ID Food or Food constituent Health Relationship Proposed wording 
559 Fructose + dextrose. Weight control. 
Carbohydrate metabolism 
and insulin sensitivity. 
Low-calorie and filling snack. 
Slow carbohydrates prevent rapid 
changes in blood sugar. 
Slow carbohydrates help to keep 
blood sugar levels even for a long 
time. 
With no rapid drops in blood sugar 
people feel more satiated, due to 
which weight control is easier. 
Fibre-rich food is good for those 
wanting to lose weight. 
Fibre does not contain energy, but is 
filling. 
Conditions of use 
- Fruit drink with 3g/100g of carbohydrates, 7.5g/serving, 15g/daily serving, of which sugar 
2.2g/100g, 5.5g/serving, 11g/daily serving of which fructose 1.6g/100g, 4,0g/serving, 
8.0g/daily serving and dextrose 0.5g/100g, 1.3g/serving, 2.5g/daily serving. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1174 
 
 
 
 
 
 
Black rice (Oriza sativa 
indica), consumed as such, 
or the bran (pigment 
fraction) of black rice used 
as a food ingredient in 
foods, in particular 
yoghurts, baked products, 
food supplements and 
certain foods for a 
particular nutritional use. 
heart health vascular 
health 
helps keep the heart and arteries 
healthy #C 
helps maintain healthy blood 
cholesterol #B 
helps protect the body tissue and cells 
from oxidative damage #A 
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 Clarification provided 
Black rice (Oriza sativa 
indica), consumed as such, 
or the bran (pigment 
fraction) of black rice used 
as a food ingredient in 
foods, in particular 
yoghurts, baked products, 
food supplements and 
certain foods for a 
particular nutritional use. 
Change to anthocyanins, 
see MS comment 
Conditions of use 
- More than 5 g black rice bran per day or the equivalent amount of bran pigment 
Comments from Member States 
Information: Black rice (Oryza sativa L. indica) is a special cultivar of the regular rice (i.e. 
brown rice, which only turns white after the aleuron layer is removed). Its aleuron layer 
(representing about 6% of total rice grain) has a higher content of anthocyanins and hence has a 
dark color.  
SE is therefore of the opinion that since anthocyanins are the active substances of Black rice, 
item 810 should instead refer to item 1445 anthocyanins, where EFSA comment is 0. 
ID Food or Food constituent Health Relationship Proposed wording 
1184 Berries (lingonberry, 
cloudberry, blueberry, 
currants, raspberry and 
strawberry). 
Cardiovascular system. Natural berries contain plenty of 
natural antioxidants (polyphenolic 
compounds, Vitamin C and 
carotenoids) and fibre but only a 
small amount of energy and sodium. 
For this reason they are very suitable 
for a heart-friendly diet. 
Conditions of use 
- The claim is not linked to the amount of berries used. According to Finnish nutritional 
recommendations, people should eat plenty of vegetables, berries and fruit, at least five 
servings per day totalling at least 400 g. 
ID Food or Food constituent Health Relationship Proposed wording 
1197 Grape juice. Maintenance of 
cardiovascular system. 
Grape juice:  
- plays an important antioxidative 
function. 
- helps to maintain a healthy 
cardiovascular system. 
Conditions of use 
- 5 - 7,5 ml/kg weight over 7 - 14 days. 
- At least 50 g per day. 
ID Food or Food constituent Health Relationship Proposed wording 
1380 Apple cider vinegar. Weight management. Helps control and normalize body 
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 weight. 
Conditions of use 
- Powder: 1,2 g. 
ID Food or Food constituent Health Relationship Proposed wording 
1409 Sauerkraut Saft 
(milchsauer vergorener 
Weißkohl (Brassica 
oleracea var. capitata). 
Clarification provided 
Sauerkraut juice (lactic 
acid fermented white 
cabbage (Brassica loeracea 
var. capitata). 
D/L-Milchsäure - 
L(+)Milchsäure regt die 
Darmperistaltik an. 
Clarification provided 
D/L-lactic acid - 
L(+)lactic acid activate 
the gut motility. 
[In German:] Sauerkrautsaft regt die 
Verdauung an. 
Clarification provided 
Helps to support the digestion / 
contributes to the normal function of 
intestinal tract / functioning of the 
stomach / sauerkaut juice activate the 
eupepsia. 
Conditions of use 
- Erwachsene, 300 Milliliter (ml), 4 bis 6 Wochen. 
- 2-3 mal wöchentlich 150 g. 
ID Food or Food constituent Health Relationship Proposed wording 
1656 Standardised Potato 
Extract 
Satiety/Weight 
management/Promotion 
of CCK release and soy 
foods. 
When taken before a meal, supports 
the body's natural satiety response 
naturally supports feelings of fullness 
after a meal 
helps manage appetite and hunger 
promotes feelings of fullness and 
satiety 
satiety aid 
helps to feel full sooner 
Conditions of use 
- Product-specific claim. 15-30 mg of proteinase inhibitors from the standardized potato 
extract ingredient, taken one hour before the meal, daily 
ID Food or Food constituent Health Relationship Proposed wording 
1667 Tomato extract, grape 
seeds extract, vitamin C 
and E, Selenium 
(Seresis Pharmaton) 
For cardiovascular health 
Clarification provided 
Maintenance of heart and 
cardiovascular health: 
Helps to protect from 
environmental stress 
acting as an antioxidant  
For maintenance of heart and 
cardiovascular health, 
Helps to improve cardiovascular 
system, general ageing process, 
immunological problems and 
protecting from environmental 
stresses 
Conditions of use 
- Target groups: Adults. Applicable to products which contain following daily dosage ranges: 
Vitamin C: 60-120 mg, Selenium: 25-50 mcg, Vitamin E: 6.7-13.4 mg, Beta-carotene: 2.4-
4.8 mg, Tomato extract standardized to 5% lycopene (25-50 mg / day), Grape seed extract 
standardized 8.5 - 13.0% proanthocyanidins (25-50 mg / day) 
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ID Food or Food constituent Health Relationship Proposed wording 
1670 Troxerutin Vascular health. 
Clarification provided 
Vascular health. 
Increases elasticity and 
strengh of blood vessels 
and vein walls (flow rate, 
distension, tonus). 
Helps improve 
endothelial function. 
Contributes to the normal functioning 
of the veins. 
Conditions of use 
- 60 mg/day. 
- 1mg Rutin. 
ID Food or Food constituent Health Relationship Proposed wording 
1763 Hesperidin (a component 
of citrus peel extract and 
precursor of hesperitin) 
(ingredient not found in the 
spanish food laws). 
Cardiovascular health. Helps maintain normal blood 
cholesterol levels/Supports heart 
health (to be evaluated by EFSA). 
Conditions of use 
- ≥ 400 mg/d. 
ID Food or Food constituent Health Relationship Proposed wording 
1767 Antler. Cardiovascular health. 1. For cardiovascular health. 
2. Improves function of the heart. 
Conditions of use 
- 0,4 g 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1806 Flavonoids from green tea, 
apple and onion 
Weight control Flavonoids, especially catechins from 
green tea, reduce the absorption of 
carbohydrates by 25%. 
Carbohydrates account for 49% of 
total energy. Thus the weight 
slimming effect is a total of 12%.  
Reduces visceral fat 
Conditions of use 
- Capsules with flavonoids from green tea (ECGC, epigallocatechin gallate), apple and onion 
(chemferol, myricetin, quercetin). According to the respondent, the “minimum effect/day” 
for synergic flavonoids is 25mg, and one capsule is enough to exceed the minimum. The 
positive effects of flavonoids increase to a certain level as the dose increases, but the effects 
do not accumulate. 
- Flavonoids: At least a daily flavonoids intake of 130 mg  
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ID Food or Food constituent Health Relationship Proposed wording 
1884 Name of Food product: 
Product-specific claim: 
sodium alginate, HCA and 
piperine. 
Description of food in 
terms of food legislation 
categories: food not 
covered by specific food 
legislation. 
Was food on Irish market 
before 1st July 2007: No 
Health benefits of food: 
Alginate forms a gel in the 
stomach and promotes an 
immediate feeling of 
satiety. It may also trap a 
portion of HCA. Piperine 
increases the 
bioavailability of the un-
trapped HCA and enhances 
satiety. 
Do benefits relate to a 
disease risk factor: No. 
Target group: Adults aged 
18 years and over with 
some exceptions. 
If exceptions describe: 
Pregnant, lactating women 
and children. Also those 
with calcium deficiency or 
brittle bones. 
Reasons for excluding 
these groups: HCA can 
influence the body’s own 
production of cholesterol 
and therefore it may 
influence indirectly the 
production of sterols. 
Pregnancy is a time of 
extreme sensitivity to 
steroid hormones so HCA 
should be avoided and also 
during lactation. Sodium 
alginate may decrease the 
absorption of calcium if 
taken concomitantly 
therefore it should be 
avoided by pregnant, 
lactating women, children 
and those with brittle bones 
or calcium deficiencies. 
Exact wording of claim as it 
appears on product: Helps manage 
appetite and hunger. 
Examples of any alternative 
wording that may be used in 
relation to claim: Contributes to 
reduce the appetite/Can help in the 
management of weight 
control/Promotes the feeling of 
fullness and satiety/Helps to fel full 
sooner/Helps to stay full 
longer/Assists weight 
management/Helps to reduce the 
appetite and inhibits conversion of 
carbohydrates to fats/Helps 
maintain a healthy level of appetite. 
Is claim a picture: No. 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 3. Names of 
nutrient/other substances and Quantity in Average daily serving: 2.20 grams sodium 
alginate, 1500.00 miligrams HCA, 10 miligrams Piperine. Weight of average daily food 
serving: 150 mililitre(s). Daily amount to be consumed to produce claimed effect: 300 
mililitre(s). Number of food portions this equates to in everyday food portions:  1. Are there 
factors that could interfere with bioavailability: Yes. Please give reason: Sodium alginate 
forms a gel when it interacts with gastric acid in the stomach. Sodium alginate my trap a 
portion of HCA in the gel thus reducing its efficacy. Piperine (black pepper extract), a 
bioavailability enhancer, acts to increase the un-trapped portion of HCA thus allowing it to 
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carry out its physiological function. Sodium alginate may also interfere with calcium in the 
body and it is therefore recommended not to take calcium supplements (or any 
supplements) concomitantly. Length of time after consumption for claimed effect to become 
apparent: It is apparent immediately. Is there a limit to the amount of food which should be 
consumed in order to avoid adverse health effects: Don't Know. Where applicable outline 
nutritional composition (g per 100g) of food: Total Fat: .01, Saturated Fat:      .00, Trans 
Fat:      .00, Sugar:      .31, Salt:      .00, Sodium:      .10. Other conditions for use: This 
beverage should be consumed as part of a varied, balanced and healthy lifestyle. Two 
beverages are to be consumed daily in order to gain benefit of satiety and no more than 3 
beverages are to be consumed daily. The entire beverage must be consumed. This product 
should be avoided by pregnant and lactating women, children and those with calcium 
deficiencies or brittle bones. 
ID Food or Food constituent Health Relationship Proposed wording 
1908 Diosmin (a component of 
citrus peel extract and 
precursor of diosmetin) 
Vascular health 
Clarification provided 
Vascular health 
Helps maintain normal blood 
circulation in the legs.  
Helps manage inflammatory 
reactions of the veins. 
Helps maintain the normal 
elasticity and integrity of the 
veins. 
Helps maintain a good venous 
blood circulation. 
Supports a normal venous 
function. 
Helps maintain healthy venous 
circulation in the legs. 
Protects veins from 
inflammatory reactions. 
Supports the strength of blood 
vessels. 
Conditions of use 
- 0.5 - 1.0 g/d 
ID Food or Food constituent Health Relationship Proposed wording 
1997 Aronia melanocarpa 
(Common Name : 
Chokeberry). 
Antioxidant 
properties/source of 
anthocyanins and 
polyphenols with 
antioxidant activity. 
Contains antioxidant/s. 
Is a source of antioxdiant/s. 
With antioxidant/s. 
Natural source of beneficial bioactive 
compounds: polyphenols 
(anthocyanins, flavonols, tannins),  
that help maintain optimum 
antioxidant status of the body. 
Conditions of use 
- Schulkinder, Erwachsene - 1500Gramm (g) getrocknete Beeren. 
- Frucht /  Äquivalent zumAnthocyanin - Gehalt von 9-15 g frischer Früchte; täglich (45 – 60 
mg Anthocyanine ber. als Cyanidin-3-0-galactosid pro Tag). 
- Fruit / The equivalence of anthocyanins content of 9-15 g of fresh fruits per day (45 – 60 
mg anthocyanins calculated as cyanidin-3-0 galactoside per day). 
ID Food or Food constituent Health Relationship Proposed wording 
2141 
 
Sinapis alba  (Common 
Name: White mustard). 
Appetite/Digestion. Contributes to appetite / helps to 
support the digestion / helps to 
support the digestive juice flow / 
contributes to the gastro-intestinal 
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 movement. 
Conditions of use 
- Semen (nasienie gorczycy białej) / 15 g na dzień. 
- Samen / 15 g pro Tag. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2159 Vitis vinifera (Common 
Name: Grape). 
Heart health. Contributes to a healthy blood 
pressure. 
Conditions of use 
- Früchte, Blätter, Samen / Üblicher Verzehr als traditionelles Lebensmittel im Rahmen einer 
ausgewogenen Ernährung / Äquivalent von 5 g Blättern pro Tag. 
- Owoc, liście, nasiona / zwykle konsumowane jako tradycyjny artykuł żywnościowy w 
normalnej diecie / równowartość 5g liścia na dzień. 
- Fruit, leaf, seed / Usual consumption as traditional foodstuff in a normal diet / The 
equivalent of 5 g of leaf per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2243 Citrullus lunatus 
(Watermelon) extract - 
ACTI-08. 
Weight loss management 
carbohydrate & lipid 
metabolism improvement. 
Helps to improve carbohydrate and 
fat metabolism of the body 
Used to facilitate the weight loss 
Helps to loose weight 
Contributes to loose weight  
Used to facilitate the weight loss  
Helps in weight control 
Contributes to body weight 
management. 
Conditions of use 
- 250 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2244 
 
 
 
 
 
 
 
 
Citrullus lunatus  
(Watermelon) extract - 
ACTI-08. 
Antioxidant properties. Good source of antioxidants 
Contains naturally occuring 
antioxidants 
Has antioxidant properties 
Acts as an antioxidants 
Contributes to the protection against 
oxidation 
Helps increase the antioxidative 
capacity of the body 
Helps preventing oxidation 
Antioxidants help protect you from 
free radicals 
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Antioxidants help protect your cells 
and tissues from oxidation 
Antioxidants contribute to the total 
antioxidant capacity of the body 
Antioxidants help to protect your 
body by reinforcing the body's 
natural defence against the effects of 
free radicals 
Conditions of use 
- 250 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2325 Prunus mume (Plum) 
extract - INP-08. 
Weight loss management 
Acid base balancer. 
Helps to balance the acidity of the 
body 
Helps to promote the acide-base 
balance of the body 
Helps to the detoxification of the 
body  
Used to facilitate the weight loss 
Helps to loose weight 
Contributes to loose weight  
Used to facilitate the weight loss 
Helps in weight control   
Contributes to body weight 
management 
Conditions of use 
- 350 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2331 Ribes nigrum - nom 
commun: blackcurrant. 
Control of weight. "Used to facilitate the weight loss in 
addition to dietetic measures"  
"Helps to loose weight in addition to 
dietetic measures"  
"Contributes to loose weight in 
addition to dietetic measures"  
"Helps to maintain the weight"  
"Contributes to maintain the weight"  
"Helps in weight control"  
Conditions of use 
- Traditional use of the leaf  / 2-4 g of leaves as an infusion one cup several times daily / 
Equivalent quantity in extract. 
ID Food or Food constituent Health Relationship Proposed wording 
2333 Rice vinegar extract - Weight loss management Helps to balance the acidity of the 
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 INRV-08. Acid base balancer. body 
Helps to promote the acide-base 
balance of the body 
Helps to the detoxification of the 
body 
Used to facilitate the weight loss 
Helps to loose weight  
Contributes to loose weight   
Used to facilitate the weight loss 
Helps in weight control  
Contributes to body weight 
management 
Conditions of use 
- 350 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2336 Rubus idaeas  (Raspberry) 
extract - BERI-08. 
Weight loss management 
Thermogenesis. 
Helps to enhance the thermogenesis 
production, wich in turn helps weight 
control    
Helps to control the appetit 
Naturally supports feeling of fullness 
after a meal  
Helps to manage appetit and hunger 
Helps to loose weight 
Contributes to loose weight 
Used to facilitate the weight loss 
Helps in weight control  
Contributes to body weight 
management 
Conditions of use 
- 300 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2652 Extract from Aronia 
melanocarpa 
antioxidant effects   helps to protect cells from the fee-
radical damage by oxidative stress 
Conditions of use 
- at least 1,5g/day 
ID Food or Food constituent Health Relationship Proposed wording 
2717 
 
 
Ribes nigrum - nom 
commun : blackcurrant 
Control of weight "Traditionally used to facilitate the 
weight loss in addition to dietetic 
measures"  
"Used to facilitate the weight loss in 
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 addition to dietetic measures" 
"Helps to loose weight in addition to 
dietetic measures" 
"Contributes to loose weight in 
addition to dietetic measures" 
"Helps to maintain the weight" 
"Contributes to maintain the weight"  
"Helps in weight control"  
Conditions of use 
- Traditional use of the leaf  / 2-4 g of leaves as an infusion one cup several times daily / 
Equivalent quantity in extract 
- Leaf. Usual consumption as traditional foodstuff in a normal diet 
ID Food or Food constituent Health Relationship Proposed wording 
2727 Grape (Vitis vinifera L)  Weight control Helps to support in weight loss 
programs. 
Helps to support slimming. 
Helps silhouette to become more 
refined. 
Useful in weight loss management. 
Conditions of use 
- 1200 mg of grape marc powder / day 
- Fruit. At least 60 mg grape extract per day 
ID Food or Food constituent Health Relationship Proposed wording 
2752 Radis noir: Raphanus niger 
(Black radish) 
Improve digestion/transit Usually recognized for helping 
digestion.   
Usually recognized for helping transit 
Conditions of use 
- Traditional use of root: raw or 20 to 50g per day of fresh extract juice  
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2788 Zea mays L. ; Common 
name : Maïs 
amincissement Facilite la perte de poids en 
complément de mesures diététiques.  
Help weight loss in addition to 
dieting 
Conditions of use 
- Partie : Style ; DJR :400 mg  
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2861 Mangosteen (Garcinia 
mangostana L) fruits and 
Control of blood lipids Mangosteen whole fruit 
juice/concentrate [contains xanthones 
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 extracts derived from the 
fruits 
which] may help to regulate blood 
lipids 
Conditions of use 
- Typical adult dosage: 30-100 ml daily of whole fruit juice. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2870 Standardisierter 
Kartoffelextrakt 
Clarification provided 
standardized potatoe 
extract 
Sättigung/ 
Gewichtsmanagement / 
Förderung  der CCK-
Ausschüttung 
Clarification provided 
satiation/weight 
management/promotion 
of CCK-discharge 
[In german : ]  hilft Ihnen, 
kontrolliert und nicht zwischen den 
Mahlzeiten  zu essen 
Clarification provided 
helps not to eat between meals 
Conditions of use 
- Other condition: produktspezifische Auslobung. 15-30 mg Proteinasehemmer aus standard. 
Kartoffelextrakt, täglich 1 Stunde vor jeder Mahlzeit zu nehmen 
- Other condition: Produktspezifische Angabe: 15-30 mg Proteasehemmer aus 
standardisiertem Kartoffelextrakt eine Stunde vor den beiden größten Mahlzeiten täglich 
ID Food or Food constituent Health Relationship Proposed wording 
2885 Natural mineral water: 
Sulphates as Mg-, Na- 
salts:  MgSO4, Na2SO4 
Digestion/Intestinal tract Sulphates promote emptying of 
bowel. 
Conditions of use 
- 15% RDA per 100 ml 
Comments from Member States 
MS clarification to CoU: 'min. 1200 mg SO42- /L, 300 mL to 1500 mL per day 
ID Food or Food constituent Health Relationship Proposed wording 
2894 Potato protein isolate satiety Increases the sense of satiety 
Elicit satiety 
Reduces appetite 
Supports weight control 
Conditions of use 
- Active component are potato protease inhibitors (PI) in pasteurized potato protein fractions 
isolated from potato tubers. The amount (w) to elicit its effect depends on the inhibitor 
activity (IA) of the protein isolate: 0.4 - 2 gram potato protein isolate (for explanation see 
Solanic document NP07104). PI can be provided by dairy, beverages, soups, meals or meal 
components. Pregnant women and people including children with a healthy bodyweight are 
advised to avoid food products which are intended to reduce caloric intake. 
ID Food or Food constituent Health Relationship Proposed wording 
3077 Beta carota (carrot juice, 
lactic acid fermented) 
Immunesystem, 
antioxidantproperties 
Supports the immune system, 
supports the natural antioxidant 
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 Clarification provided 
Strengthens the body's 
naturel defense through 
antioxidantproperties 
system in the body 
Conditions of use 
- At least 1 glass ( = 150 ml) lactic acid fermented carrot juice per day 
Comments from Member States 
Additionally the example of wording is modified as follows:Strengthens the body's natural 
defense. Helps maintain the immune system, the body's natural defenses. Contains a high 
amount of naturally occurring antioxidants 
ID Food or Food constituent Health Relationship Proposed wording 
3101 Fat-reduced cream powder 
[rich source of milk 
sphingomyelin (a 
sphingolipid)] 
Cardiovascular health 
Clarification provided 
Cardiovascular health 
Contributes to heart 
health and artery health 
by helping maintain 
normal blood cholesterol 
levels. Helps reduce 
cholesterol levels in 
people with elevated 
blood cholesterol. 
Helps control blood cholesterol; for 
people with elevated blood 
cholesterol 
Conditions of use 
- ≥0.7g milk sphingomyelin, corresponding to 13.5g fat-reduced cream powder, per eating 
occasion 
ID Food or Food constituent Health Relationship Proposed wording 
3516 Plante : Pomme  
Malus communis (=syn. 
Pirus malus) (Apple)  
Clarification provided 
Apple - Malus communis 
(=syn. Pirus malus)  
Digestion 
Clarification provided 
Digestion = increase the 
consistency of stools 
Reconnu pour faciliter la 
digestion/Reconnu pour contribuer à 
un confort digestif/reconnu pour 
favoriser le transit par un effet de lest 
Clarification provided 
Traditionally used to facilitate the 
digestion / traditionally used to 
contribute to the digestive comfort / 
traditionally used to facilitate a good 
digestion / traditionally used to 
enhance le digestion by an effect of 
load 
Conditions of use 
- Fruit/ Consommation traditionnelle dans le cadre d’une alimentation normale/l'équivalent 
de 1g par jour 
ID Food or Food constituent Health Relationship Proposed wording 
3595 SproutGarden® Sprout 
Blend 
Excellent source of 
sulforaphane known to 
SproutGarden® is an excellent 
source of sulforaphane, a compound 
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help in the management 
of heart health 
that has been associated with the 
maintenance of cardiovascular health. 
Conditions of use 
- 1-5 grams per dose 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
3726 (Ananas sativus) obtained 
from fruit juice and stems                   
AND Dry aqueous extract 
of pineapple standardized 
at 2% of bromelain 
slimming (cellulitis 
draining) 
Recommended during slimming diet, 
at the same time of dietary measures.  
Pineapple is a tropical plant whose 
stems contain bromelain, a 
proteolytic enzymatic complex.  
Bromelain is a proteolytic enzyme 
with anti-edematous activity which 
can help to drain tissues with 
cellulitis. 
Conditions of use 
- 1160 mg of pineapple powder AND 96 mg of dry aqueous extract of pineapple 
ID Food or Food constituent Health Relationship Proposed wording 
4252 Glycomacropeptide Weight 
management/satiety 
Recognized for hunger feeling 
reduction 
Conditions of use 
- 112 mg/day 
ID Food or Food constituent Health Relationship Proposed wording 
4288 Beta-carotene, vitamine C, 
vitamine E et sélénium 
antioxydant action Protect fatty acids of skin cell 
membranes from oxidation after sun 
exposure 
Conditions of use 
- 100% RDAs 
ID Food or Food constituent Health Relationship Proposed wording 
4290 Vitamine E and Sélénium antioxydant action protect fatty acids of skin cell 
membranes from oxidation after sun 
exposure 
Conditions of use 
- Vitamin E:100%RDAs. Selenium:50µg/day 
ID Food or Food constituent Health Relationship Proposed wording 
4406 Ganoderma lucidum-
Mashroom-Reishi 
mushroom 
Blood Cholesterol Helps to decrease the cholesterol 
level 
Conditions of use 
-  150 – 350 mg a day 
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ID Food or Food constituent Health Relationship Proposed wording 
4509 Zea mays-Radicles-Maize, 
Cornsilk 
help restoration of 
myocardial tissue 
Helps to structure and function of 
heart 
Conditions of use 
- Radicles / Usual consumption as traditional foodstuff in a normal diet./ The equivalent of 
135 - 180  mg    per day. 
ID Food or Food constituent Health Relationship Proposed wording 
4709 Fructose, L/Carnitine Weight Control instant drink which helps burning fats 
/ accelerate the fats metabolism / 
increase physical performances and 
effort resistance 
Conditions of use 
- 2 envelopes daily / Not for diabetics. 
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GLOSSARY AND ABBREVIATIONS 
CAT  Catalase 
DNA  Deoxyribonucleic acid  
DCF   Dichlorofluorescein 
FRAP   Ferric reducing ability of plasma 
GPx  Glutathione peroxidase 
GSH   Glutathione 
HDL  High-density lipoproteins 
LDL  Low-density lipoproteins 
MDA  Malondialdehyde 
ORAC  Oxygen radical absorbance capacity 
PON  Paraoxonase  
ROS  Reactive oxygen species 
SOD  Superoxide dismutase 
TBARS Thiobarbituric acid-reactive substances 
TEAC   Trolox-equivalent antioxidant capacity 
TRAP   Total reactive antioxidant potential  
UV  Ultra-violet 
